Applications

• Fibers with lipophilic properties / weight management support
• Positive action on blood lipid parameters
• Link with cardiovascukar risks and Metabolic Syndrome (Syndrome X) diagnosis
  

Nature

• Patented powder of Opuntia ficus indica cactus leaves
• Certified Organic (by Ecocert, F32600)
  

Active content

• Soluble and insoluble fiber of Opuntia ficus-indica cactus
  

Scientific Background

• In vitro study: gastrointestinal model

• 2001: 2g of NeOpuntia®, associated to a test meal absorbs part of total fatty acids during the 4-hours in vitro test.
• 2004 : Comparison between NeOpuntia® and a branded chitosan : NeOpuntia® decreases fatty acids bio-availability, whereas chitosan shows no effect.
• 2005: NeOpuntia®'s lipophilc properties are confirmed when associated with a traditional American breakfast.

• Pilot clinical study

• 2003: the double blind, placebo-controlled study suggests that NeOpuntia®  could increase fat excretion by 27%.

• Clinical Study (PUBLISHED) :
  
  E. Linares. The effect of NeOpuntia® on blood Lipid parameters - risk factors for the Metabolic Syndrome (Syndrome X). Advances in Therapy®, vol. 24 N°5 ; september-october 2007. Study conducted on 68 females divided into 2 groups (NeOpuntia® and Placebo), during 42 days :

• On the total population, NeOpuntia®  increases HDL cholesterol level, with a significant trend (+0.0217 g/l)
• In women 45 years or older, NeOpuntia® significantly increases HDL cholesterol level (p=0,029)
• Almost 40% of women in the NeOpuntia® group are no longer diagnosed with Metabolic Syndrome, against only 8% for the Placebo group.

Presentation

• Fine, light-green powder
• Also available in granulated and fluid form